Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer

Inclusion Criteria: * Locally advanced breast cancer diagnosed by guided core biopsy * T \> 2 cm (any N), or any T and node positive (needle biopsy is required) * Non-metastatic disease assessed by computed tomography and bone scintigraphy * Histological grade 2 and Ki67 \> 15% or * Histological grade 3 or * Any triple negative (TN) or * Inflammatory breast cancer (IBC) * Normal left ventricular ejection fraction (LVEF) * HER2-negative disease Exclusion Criteria: * Another malignancy within the last 5 years (except curatively treated skin carcinoma, in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular carcinoma of the breast) * Clinically significant comorbidities as cardiovascular diseases, chronic obstructive pulmonary disease (COPD), renal or liver failure, psychiatric disorders * LVEF value below institutional limits of normal * Predominant lobular carcinoma histology * Grade 1 tumors * Detected or suspicious distant metastasis * Neutrophils less than 1,500/µL, platelets less than 100,000/µL, hemoglobin less than 10 g/dL, AST more than 2.5x upper limit of normal (ULN), total bilirubin more than ULN, alkaline phosphatase more than 1.5x ULN * Male sex * HER2-positive breast cancer